Ignite Creation Date:
2024-05-05 @ 11:50 AM
Last Modification Date:
2024-10-26 @ 9:14 AM
Study NCT ID:
NCT00146003
Status:
COMPLETED
Last Update Posted:
2008-08-07
First Post:
2005-09-01
Brief Title:
Efalizumab for Eczema
Sponsor:
University of Medicine and Dentistry of New Jersey
Organization:
Rutgers The State University of New Jersey
Study Overview
Official Title:
Investigator-Initiated Trial of Efalizumab for Atopic Dermatitis A Proof of Concept Study in Adults
Status:
COMPLETED
Status Verified Date:
2008-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to demonstrate a measurable improvement on a validated scale in a small population of adult patients with atopic dermatitis eczema
Detailed Description:
The study involves administration of efalizumab previously approved for psoriasis to ten adult patients with atopic dermatitis Biologic plausibility rests on similarities in pathophysiology of the two conditions The drug efalizumab will be administered according to the dosing approved for plaque psoriasis for a period of 24 weeks The subjects will self-administer efalizumab weekly and measurements will be performed on a monthly basis Efalizumab is not being compared to placebo or other drugs
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None